Related Experiment Video
Updated: Apr 21, 2026
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
Published on: May 20, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas
Charlie Gourley1, John Farley, Diane M Provencher
1*University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh, United Kingdom; †Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St Joseph's Hospital and Medical Center, Phoenix, AZ; ‡Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Institut du Cancer de Montréal, Montreal, Quebec, Canada, Division of Gynecologic Oncology, Université de Montréal, Montreal, Quebec, Canada; §Dipartimento di Oncologia Uroginecologica, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G Pascale, IRCCS, Napoli, Italy; ∥Division of Cancer Medicine, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia; ¶Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany; #Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland; **Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea; ††Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France; ‡‡The Beatson West of Scotland Cancer Centre, Gartnavel Hospital, University of Glasgow, Glasgow, United Kingdom; §§Département d'Oncologie médicale adulte, Centre Léon Bérard, Lyon, France; and ∥∥Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract:
Low-grade serous ovarian cancer is a recently described histological subtype of ovarian cancer that is clinically and molecularly distinct from the 4 other main histological subtypes (high-grade serous, clear cell, endometrioid, and mucinous). In particular, it differs from high-grade serous ovarian cancer in that it presents at a much younger age, is more indolent, and is relatively chemoresistant. Very few clinical trials have been performed exclusively in this tumor type; and as such, specific data guiding optimal management are limited.
